NASDAQ:COAG Hemab Therapeutics (COAG) Stock Price, News & Analysis $41.45 +1.03 (+2.55%) As of 10/30/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Hemab Therapeutics Stock (NASDAQ:COAG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Hemab Therapeutics alerts:Sign Up Key Stats Today's Range$39.38▼$42.8550-Day Range$28.37▼$49.6552-Week Range$23.00▼$55.42Volume765,549 shsAverage Volume418,508 shsMarket Capitalization$1.94 billionP/E RatioN/ADividend YieldN/APrice Target$54.71Consensus RatingModerate Buy Company Overview Hemab Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious bleeding disorders. The company’s research is aimed at addressing conditions in which patients experience inadequate clot formation or difficulty controlling bleeding, including rare inherited and acquired disorders. Hemab’s lead investigational program, HMB-001, is being developed as a potential treatment for Glanzmann thrombasthenia, a rare inherited platelet disorder that can cause severe and recurring bleeding. The company is also evaluating additional applications for its therapeutic platform in other bleeding conditions. Hemab Therapeutics was founded in 2019 and has operations in the United States and Denmark. Its programs remain investigational and are subject to clinical development and regulatory review; the company does not yet have an approved commercial product.AI Generated. May Contain Errors. Read More Hemab Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreCOAG MarketRank™: 3.778759911605 of 5 starsHemab Therapeutics scored higher than 76% of companies evaluated by MarketBeat, and ranked 115th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingHemab Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialHemab Therapeutics has a consensus price target of $54.71, representing about 32.0% upside from its current price of $41.45.Amount of Analyst CoverageHemab Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Hemab Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Hemab Therapeutics are expected to grow in the coming year, from ($3.10) to ($2.62) per share. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.77% of the float of Hemab Therapeutics has been sold short.Short Interest Ratio / Days to CoverHemab Therapeutics has a short interest ratio ("days to cover") of 7.81.Change versus previous monthShort interest in Hemab Therapeutics has recently decreased by 6.75%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHemab Therapeutics does not currently pay a dividend.Dividend GrowthHemab Therapeutics does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment1.07 News SentimentHemab Therapeutics has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Hemab Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for COAG on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Hemab Therapeutics insiders have not sold or bought any company stock.Percentage Held by InstitutionsHemab Therapeutics has minimal institutional ownership at this time.Read more about Hemab Therapeutics' insider trading history. Receive COAG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hemab Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. COAG Stock News HeadlinesHemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Stock Has Average Target Price of $54.71October 31 at 3:16 AM | americanbankingnews.comCOAG - Hemab Therapeutics Holdings, Inc.October 24, 2026 | seekingalpha.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.October 31 at 1:00 AM | Weiss Ratings (Ad)Rodman & Renshaw initiates coverage of Hemab Therapeutics Holdings with buyOctober 13, 2026 | msn.comHemab Therapeutics: The Market Is Pricing One Rung Of A Four-Rung LadderSeptember 29, 2026 | seekingalpha.comHemab Therapeutics Holdings (COAG) Joins Russell Indices, Is The Stock Still Trading At A Discount?September 29, 2026 | finance.yahoo.comHemab Therapeutics Holdings, Inc. Announces Board and Committee Changes, Effective September 24, 2026September 25, 2026 | marketscreener.comMHemab Therapeutics Strengthens Board of Directors with Appointment of Keli WalbertSeptember 24, 2026 | globenewswire.comSee More Headlines COAG Stock Analysis - Frequently Asked Questions How have COAG shares performed this year? Hemab Therapeutics' stock was trading at $34.00 on April 30, 2026. Since then, COAG stock has increased by 21.9% and is now trading at $41.45. How were Hemab Therapeutics' earnings last quarter? Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) posted its earnings results on Tuesday, August, 11th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by $0.17. When did Hemab Therapeutics IPO? Hemab Therapeutics (COAG) raised $285 million in an initial public offering on Friday, May 1st 2026. The company issued 16,750,000 shares at $16.00-$18.00 per share. When did Hemab Therapeutics' lock-up period expire? Hemab Therapeutics's lock-up period expired on Wednesday, October 28th. Hemab Therapeutics had issued 16,750,000 shares in its public offering on May 1st. The total size of the offering was $301,500,000 based on an initial share price of $18.00. Since the expiration of Hemab Therapeutics' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted. Who are Hemab Therapeutics' major shareholders? Top institutional shareholders of Hemab Therapeutics include Profund Advisors LLC (0.02%) and China Universal Asset Management Co. Ltd.. View institutional ownership trends. How do I buy shares of Hemab Therapeutics? Shares of COAG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/11/2026Today10/31/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:COAG CIK2114044 Webwww.hemab.com Phone(452) 138-7627FaxN/AEmployees59Year Founded2019Price Target and Rating Average Price Target for Hemab Therapeutics$54.71 High Price Target$70.00 Low Price Target$36.00 Potential Upside/Downside+32.0%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio35.85 Quick Ratio35.85 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares46,710,000Free FloatN/AMarket Cap$1.94 billion OptionableN/A BetaN/A Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:COAG) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersYour free stock pick for todayElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredDoes your nest egg have an expiration date?A $250,000 nest egg growing at 5% a year and paying out $2,500 a month runs dry in just over a decade. Start w...Investors Alley | SponsoredLast note from me on thisJoel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gol...The Cycle Code | SponsoredWhat Elon Musk's Cybercab Reveal Could Mean for InvestorsJeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemab Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hemab Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
